Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coya’s Low-Dose Interleukin 2 (IL-2) Product Candidate - Allele Capital

https://ir.coyatherapeutics.com/news/news-details/2023/Coya-Therapeutics-Inc.-Announces-Expansion-of-Exclusive-Worldwide-Licensing-Agreement-with-ARScience-Biotherapeutics-Inc.-for-Development-and-Commercialization-of-COYA-301-Coyas-Low-Dose-Interleukin-2-IL-2-Product-Candidate/default.aspx